* pazienti naїve all'insulina = senza pregressa esposizione insulinica

Referenze

1. Aroda VR et al. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet
Diabetes Endocrinol 2019; 7 (8): 596-605.

2. Xultophy® Riassunto delle caratteristiche del prodotto.

3. Fadini GP et al. IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX
Observational Study. Diabetes Ther. 2022 Aug;13(8):1483-1497. doi: 10.1007/s13300-022-01287-z. 

4. Linjawi S, Bode BW, Chaykin LB, et al. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type
2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 2017;8(1):101–114.

5. Philis-Tsimikas A et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes Metab 2019. 21: 1399-1408.

6. Gough SCL, et al. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab 2015; 17 (10): 965-973.

Xultophy® AIC n. 043619030 - Classe A - Prezzo al pubblico 370,98 €. Medicinale soggetto a prescrizione medica (RR).

Per RCP Xultophy® clicca qui

Novo Nordisk e Xultophy® sono marchi registrati di proprietà della Novo Nordisk A/S Danimarca.

Materiale promozionale depositato presso AIFA in data 12/01/2024 - Codice deposito aziendale IT23XUM00044.

Materiale destinato unicamente agli operatori sanitari. Vietata la distribuzione o l’esposizione al pubblico.